Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis
In this exploratory analysis, temporary interruptions of Atez or Bev were not associated with worse survival outcomes in patients with unresectable HCC. Prospective studies are needed to validate these findings.
Authors
- Xiaoqian Xu (ORCID: https://orcid.org/0000-0003-1888-4046)
- Jidong Jia (ORCID: https://orcid.org/0000-0002-4673-8890)
- Yuanyuan Kong (ORCID: https://orcid.org/0000-0002-2586-1443)
- You‐Wen He
- Cheng Huang (ORCID: https://orcid.org/0000-0002-4575-1233)
- Hong You (ORCID: https://orcid.org/0000-0001-9409-1158)
- Shun Li
- Hao Wang (ORCID: https://orcid.org/0000-0002-9131-0199)
- Wei‐Ming Li (ORCID: https://orcid.org/0000-0001-6155-0696)
- Lichen Shi
Institutions
- Duke University (US)
- Capital Medical University (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Beijing Friendship Hospital (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf269
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Capital Medical University
- Beijing Municipal Health Commission
- National Key Research and Development Program of China